INCOME funds often trade at a premium to NAV, straight equity funds like this RARELY do. Current NAV is 8.29, this will be reduced by the .63 capital gains distribution in early January, you had to own as of last Weds, to be eligible for this tho. This stock is doomed, it WILL trade back down UNDER NAV, which will soon be 7.66! Get out, get out now!!
Largest in China are 1, QIHU, 2. Venustech 3. China Jinchen Security Technology Co.,Ltd 4.Beijing Jiangmin New Sci. & Tech. Co., Ltd. 5. Beijing Rising Information Technology Co., Ltd.
It really isn't a "dividend", a year-end distribution of $0.635 per share which is estimated to consist of $0.596 per share from net long-term capital gains, and $0.039 per share from short-term capital gains. Those are taxable.
It will begin trading "ex-dividend" on December 26, 2014. Friday. Then Katy Bar the Door. Everyone will want out Friday. No more "dividend". Also more insider selling tonight!! They know what this is worth, NAV = $8.27.
Bangcle not even in top 10
ISSUER: HERZFELD CARIBBEAN BASIN FUND INC
FILER: HERZFELD THOMAS J
DATE TRANSACTION SHARES PRICE VALUE
12/19/14-12/22/14 Sale 200,000 $12.30 $2,460,400
from June 2014: LeBow Alpha received 2,232,629 shares of the Issuer's common stock for membership interests it previously held in Signal Genetics LLC, based on the IPO's offering price.... OLD NEWS!
We are offering shares of our common stock pursuant to this prospectus.
Our common stock is listed on The NASDAQ Capital Market under the symbol “SGNL”. On January 14, 2015, the last reported sale price of our common stock on The NASDAQ Capital Market was $3.23 per share. from S-1...WAKE UP PEOPLE!!
will be 7M shares outstanding Tues, how do u get 59%?, absurd.
reported 1/29/14 last year, OVERDUE!!
so now you are saying they have selling it for 5 years WITHOUT FDA approval ?? no way, ..conditional approval is for a Clinical Trial, there won't be huge demand for this test, for Clinical Trials, how many clinical trials are going to be run for Multiple Myeloma ? They only get $166 per test. After 5 years of selling that test, they lost $11.28 per share last year. They sold 936 tests Quarter ending June 2013, and 899 tests Quarter ending June 2014, so sales are decelerating. So this conditional approval is for 60 subjects, 14 enrolled per year. So they will see revenue of $2324.00 per year, and a total of $9960.00 for this trial.
and NOW they are FREE TO SELL, Lock Up over in December 2014
secondary imminent Signal Genetics files to sell $9.09M of common stock
the test has been approved by the FDA since 2010! Dec. 1, 2010 /PRNewswire/ -- Signal Genetics, the parent company of Myeloma Health, a privately held predictive genetic testing company focused on oncology, today announced the launch of their revolutionary molecular test for individuals diagnosed with multiple myeloma, MyPRS™.